Substance / Medication

Pexidartinib

SNOMED 789180004 UMLS C4287804

Overview

Active Ingredient

pexidartinib

RxNorm CUI

2183102

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Fibrous histiocytoma of tendon sheath

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704Phase 4Completed32 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.

Benner Brooke, Good Logan, Quiroga Dionisia et al. · Drug Des Devel Ther · 2020

PMID: 32440095Meta-AnalysisFull text (PMC)

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.

Wagner Andrew J, Tap William D, Bauer Sebastian et al. · Oncologist · 2025

PMID: 40613752RCTFull text (PMC)

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.

Rugo Hope S, Campbell Mike, Yau Christina et al. · Breast Cancer Res Treat · 2025

PMID: 39625569RCTFull text (PMC)

Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.

Healey John H, Tap William D, Gelhorn Heather L et al. · Clin Orthop Relat Res · 2023

PMID: 36001000RCTFull text (PMC)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.

Zahir Hamim, Greenberg Jonathan, Shuster Dale et al. · Clin Pharmacokinet · 2022

PMID: 36264536TrialFull text (PMC)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.

Yin Ophelia, Wagner Andrew J, Kang Jia et al. · J Clin Pharmacol · 2021

PMID: 33043474TrialFull text (PMC)

Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.

Zahir Hamim, Kobayashi Fumiaki, Zamora Cynthia et al. · J Clin Pharmacol · 2021

PMID: 32918831TrialFull text (PMC)

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.

Van De Sande Michiel, Tap William D, Gelhorn Heather L et al. · Acta Orthop · 2021

PMID: 33977825TrialFull text (PMC)

Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.

Boal Lauren H, Glod John, Spencer Melissa et al. · Clin Cancer Res · 2020

PMID: 32943455TrialFull text (PMC)

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.

Smith Catherine C, Levis Mark J, Frankfurt Olga et al. · Blood Adv · 2020

PMID: 32330242TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Pexidartinib (substance)
SNOMED CT: 789180004
UMLS CUI: C4287804
RxNorm CUI: 2183102

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.